Prothena to Report Second Quarter 2023 Financial Results on August 3
27 Julho 2023 - 5:05PM
Business Wire
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
biotechnology company with a robust pipeline of investigational
therapeutics built on protein dysregulation expertise, today
announced that it will report its second quarter and first six
months of 2023 financial results on Thursday, August 3, 2023 after
the close of the U.S. financial markets.
Consistent with past practice, the Company will not be
conducting a conference call in conjunction with this financial
results release on August 3.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics with the potential to change the
course of devastating neurodegenerative and rare peripheral amyloid
diseases. Fueled by its deep scientific expertise built over
decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases. For more information, please
visit the Company’s website at www.prothena.com and follow the
Company on Twitter @ProthenaCorp.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727614325/en/
Investors Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Prothena (NASDAQ:PRTA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Prothena (NASDAQ:PRTA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024